Warburg Pincus group to buy control of rare disease pharmacy PANTHERx

What's the deal? A Warburg Pincus-led investor group has agreed to acquire a controlling interest in PANTHERx Rare, the largest independent rare disease pharmacy in the US. The stake is being bought from Nautic PartnersDealroom has a profile for this one. Try Dealroom →, General Atlantic, and The Vistria GroupDealroom has a profile for this one. Try Dealroom →. Nautic Partners and PANTHERx management will remain significant shareholders.

What's the endgame? PANTHERx pioneered the rare pharmacy model, helping patients access and stay on complex therapies through clinical expertise and high-touch support. The deal is meant to back the company as an independent, rare-focused platform while preserving its patient-first, manufacturer-aligned model.

Why now? The Pittsburgh-based company had been backed since 2022 by its three exiting investors, who helped it scale. Warburg Pincus described rare disease as one of "the fastest-growing areas of healthcare."

What they're saying: "PANTHERx is a standout healthcare platform with an exceptional management team, proven execution, and deep specialization," said T.J. Carella, head of healthcare at Warburg Pincus. Chief executive officer Bansi Nagji said the deal "reinforces our position as an independent, rare-focused pharmacy" and supports investment in people, capabilities, and technology.

What could go wrong? Financial terms were not disclosed. The transaction is expected to close in the coming months, subject to customary conditions and regulatory approvals. J.P. Morgan Securities advised Warburg Pincus. Centerview Partners and Goldman Sachs advised PANTHERx.

The signal: The deal underscores private equity's continued appetite for specialty pharmacy assets serving rare disease patients, a niche where high-cost therapies and complex care create durable demand — and prompt investors to hand assets from one sponsor to the next.

Read more: PR Newswire